+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Butorphanol Market by End-user Type (Ambulatory Surgical Centers, Clinics, Hospitals), Application Area (Analgesia, Anesthesia, Labor and Delivery), Product Type, Drug Classification, Dosage Form, Patient Demographics, Industry Usage - Global Forecast 2025-2030- Product Image
Butorphanol Market by End-user Type (Ambulatory Surgical Centers, Clinics, Hospitals), Application Area (Analgesia, Anesthesia, Labor and Delivery), Product Type, Drug Classification, Dosage Form, Patient Demographics, Industry Usage - Global Forecast 2025-2030- Product Image
Sale

Butorphanol Market by End-user Type (Ambulatory Surgical Centers, Clinics, Hospitals), Application Area (Analgesia, Anesthesia, Labor and Delivery), Product Type, Drug Classification, Dosage Form, Patient Demographics, Industry Usage - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • November 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011533
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Butorphanol Market grew from USD 271.47 million in 2023 to USD 283.74 million in 2024. It is expected to continue growing at a CAGR of 4.30%, reaching USD 364.75 million by 2030.

Butorphanol is an opioid analgesic often used in pain management, particularly for moderate to severe pain, with applications extending to veterinary medicine. Its versatility is underscored by multiple delivery methods, including nasal spray, injection, and veterinary formulations, making it invaluable in clinical and animal medical practices. This market is driven by the rising demand for effective pain management solutions due to increasing cases of chronic pain, cancer, and surgeries globally. The growing emphasis on reducing post-operative pain in animals also spurs its use in veterinary applications.

A critical influencing factor for market growth is ongoing research into new formulations and delivery mechanisms, enhancing patient and animal compliance. Potential opportunities lie in expanding the use of butorphanol in emerging markets with underserved needs for opioid analgesics and focusing on low-dose formulations that reduce potential side effects.

Strategic partnerships with veterinary and healthcare facilities can strengthen market share and presence. However, strict regulatory requirements and potential abuse pose considerable challenges. Regulatory bodies' vigilance in ensuring drugs are not misused has necessitated stringent marketing and distribution controls, which may limit rapid market expansion.

Furthermore, awareness about the risks associated with opioid use and the rise of alternative pain management therapies present additional hurdles. Nonetheless, innovation opportunities exist in developing combination therapies that integrate butorphanol with non-opioid agents to optimize efficacy while minimizing addiction potential. Additionally, research into non-invasive delivery systems could open new avenues for product differentiation. As the market continues to be shaped by developments in healthcare policies and pain management practices, understanding the delicate balance between efficacy, safety, and regulatory compliance will be crucial for stakeholders aiming for long-term success and sustainable growth.

Understanding Market Dynamics in the Butorphanol Market

The Butorphanol Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Government initiatives promoting safer opioid prescriptions underscoring the relevance of butorphanol
    • Increasing animal healthcare investments affecting the demand for veterinary formulations of butorphanol
    • Technological innovations in drug delivery systems improving the accessibility and efficacy of butorphanol
  • Market Restraints
    • Examining key factors limiting the expansion prospects for butorphanol across diverse regions
    • The role of increasing concerns over potential addiction risks in restraining butorphanol demand
    • The impact of stringent prescription guidelines on the accessibility of butorphanol for patients
  • Market Opportunities
    • Integrating AI-driven analytics to predict consumer demand and optimize distribution channels for butorphanol
    • Establishing butorphanol's brand as a leader in migraine treatment through tailored awareness campaigns
    • Exploring butorphanol's potential in postoperative care to reduce dependence on traditional opioids
  • Market Challenges
    • Responding to evolving consumer preferences and demands influencing the butorphanol market
    • Anticipating changes in prescribing practices and medical guidelines impacting butorphanol usage
    • Ensuring market penetration in emerging economies and addressing related socio-economic barriers

Exploring Porter’s Five Forces for the Butorphanol Market

Porter’s Five Forces framework further strengthens the insights of the Butorphanol Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Butorphanol Market

External macro-environmental factors deeply influence the performance of the Butorphanol Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Butorphanol Market

The Butorphanol Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Butorphanol Market

The Butorphanol Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Butorphanol Market

The Butorphanol Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Butorphanol Market, highlighting leading vendors and their innovative profiles. These include Akorn, Inc., Amneal Pharmaceuticals, Inc., Aurobindo Pharma USA, Inc., BioDelivery Sciences International, Inc., Egalet Corporation, Endo Pharmaceuticals Inc., Esteve Pharmaceuticals, Fresenius Kabi USA, LLC, Hikma Pharmaceuticals PLC, Hospira, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Mylan N.V., Novartis International AG, Pfizer Inc., Purdue Pharma L.P., Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Butorphanol Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • End User Type
    • Ambulatory Surgical Centers
      • Day Procedures
      • General Surgery
    • Clinics
      • Orthopedic Clinics
      • Pain Management Specialists
    • Hospitals
      • ICU Management
      • Pain Management Teams
    • Individual Consumers
      • Home Care Pain Management
      • Prescription Holders
  • Application Area
    • Analgesia
      • Chronic Pain
      • Postoperative Pain
    • Anesthesia
      • Conscious Sedation
      • Pre-anesthesia
    • Labor and Delivery
      • Epidural Administration
      • Spinal Administration
    • Migraine Management
      • Acute Migraine
      • Prevention of Migraine
  • Product Type
    • Injection
      • Multiple-Use
      • Single-Use
    • Nasal Spray
      • Over-the-Counter Sprays
      • Prescription Nasal Sprays
    • Patch
      • Long-Term Usage
      • Short-Term Usage
    • Tablet
      • Extended-Release Tablets
      • Quick-Release Tablets
  • Drug Classification
    • Agonist-Antagonist Opioid
      • Full Antagonists
      • Partial Agonists
    • Controlled Substances
      • Patient Compliance Programs
      • Prescription Regulations
    • Scheduled Drugs
      • Potential Schedule Adjustments
      • Schedule IV
  • Dosage Form
    • Administration Frequency
      • Multiple Daily Dosages
      • Single Administration
    • Milligrams Per Administration
      • Effective Dose
      • Tapering Doses
    • Mode of Administration
      • Intravenous Administration
      • Nasal Administration
      • Oral Administration
  • Patient Demographics
    • Age Groups
      • Adults
      • Geriatrics
      • Pediatrics
    • Gender
      • Female
      • Male
    • Health Condition
      • Allergies
      • Comorbidities
      • Pain Condition
  • Industry Usage
    • Pharmaceutical Companies
      • Brand Drugs
      • Generic Drugs
    • Research and Development
      • Clinical Trials
      • Pre-clinical Studies
    • Training and Simulation
      • Medical Training
      • Patient Awareness Programs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States (California, Florida, Illinois, New York, Ohio, Pennsylvania, Texas)
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  • Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  • Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  • Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  • Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  • Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  • What is the current size of the market, and how is it expected to grow?
  • Which products, segments, and regions present the most attractive investment opportunities?
  • What are the prevailing technology trends and regulatory factors influencing the market?
  • How do top vendors rank regarding market share and competitive positioning?
  • What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Government initiatives promoting safer opioid prescriptions underscoring the relevance of butorphanol
5.1.1.2. Increasing animal healthcare investments affecting the demand for veterinary formulations of butorphanol
5.1.1.3. Technological innovations in drug delivery systems improving the accessibility and efficacy of butorphanol
5.1.2. Restraints
5.1.2.1. Examining key factors limiting the expansion prospects for butorphanol across diverse regions
5.1.2.2. The role of increasing concerns over potential addiction risks in restraining butorphanol demand
5.1.2.3. The impact of stringent prescription guidelines on the accessibility of butorphanol for patients
5.1.3. Opportunities
5.1.3.1. Integrating AI-driven analytics to predict consumer demand and optimize distribution channels for butorphanol
5.1.3.2. Establishing butorphanol's brand as a leader in migraine treatment through tailored awareness campaigns
5.1.3.3. Exploring butorphanol's potential in postoperative care to reduce dependence on traditional opioids
5.1.4. Challenges
5.1.4.1. Responding to evolving consumer preferences and demands influencing the butorphanol market
5.1.4.2. Anticipating changes in prescribing practices and medical guidelines impacting butorphanol usage
5.1.4.3. Ensuring market penetration in emerging economies and addressing related socio-economic barriers
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Butorphanol Market, by End User Type
6.1. Introduction
6.2. Ambulatory Surgical Centers
6.2.1. Day Procedures
6.2.2. General Surgery
6.3. Clinics
6.3.1. Orthopedic Clinics
6.3.2. Pain Management Specialists
6.4. Hospitals
6.4.1. ICU Management
6.4.2. Pain Management Teams
6.5. Individual Consumers
6.5.1. Home Care Pain Management
6.5.2. Prescription Holders
7. Butorphanol Market, by Application Area
7.1. Introduction
7.2. Analgesia
7.2.1. Chronic Pain
7.2.2. Postoperative Pain
7.3. Anesthesia
7.3.1. Conscious Sedation
7.3.2. Pre-anesthesia
7.4. Labor and Delivery
7.4.1. Epidural Administration
7.4.2. Spinal Administration
7.5. Migraine Management
7.5.1. Acute Migraine
7.5.2. Prevention of Migraine
8. Butorphanol Market, by Product Type
8.1. Introduction
8.2. Injection
8.2.1. Multiple-Use
8.2.2. Single-Use
8.3. Nasal Spray
8.3.1. Over-the-Counter Sprays
8.3.2. Prescription Nasal Sprays
8.4. Patch
8.4.1. Long-Term Usage
8.4.2. Short-Term Usage
8.5. Tablet
8.5.1. Extended-Release Tablets
8.5.2. Quick-Release Tablets
9. Butorphanol Market, by Drug Classification
9.1. Introduction
9.2. Agonist-Antagonist Opioid
9.2.1. Full Antagonists
9.2.2. Partial Agonists
9.3. Controlled Substances
9.3.1. Patient Compliance Programs
9.3.2. Prescription Regulations
9.4. Scheduled Drugs
9.4.1. Potential Schedule Adjustments
9.4.2. Schedule IV
10. Butorphanol Market, by Dosage Form
10.1. Introduction
10.2. Administration Frequency
10.2.1. Multiple Daily Dosages
10.2.2. Single Administration
10.3. Milligrams Per Administration
10.3.1. Effective Dose
10.3.2. Tapering Doses
10.4. Mode of Administration
10.4.1. Intravenous Administration
10.4.2. Nasal Administration
10.4.3. Oral Administration
11. Butorphanol Market, by Patient Demographics
11.1. Introduction
11.2. Age Groups
11.2.1. Adults
11.2.2. Geriatrics
11.2.3. Pediatrics
11.3. Gender
11.3.1. Female
11.3.2. Male
11.4. Health Condition
11.4.1. Allergies
11.4.2. Comorbidities
11.4.3. Pain Condition
12. Butorphanol Market, by Industry Usage
12.1. Introduction
12.2. Pharmaceutical Companies
12.2.1. Brand Drugs
12.2.2. Generic Drugs
12.3. Research and Development
12.3.1. Clinical Trials
12.3.2. Pre-clinical Studies
12.4. Training and Simulation
12.4.1. Medical Training
12.4.2. Patient Awareness Programs
13. Americas Butorphanol Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Butorphanol Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Butorphanol Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BUTORPHANOL MARKET MULTI-CURRENCY
FIGURE 2. BUTORPHANOL MARKET MULTI-LANGUAGE
FIGURE 3. BUTORPHANOL MARKET RESEARCH PROCESS
FIGURE 4. BUTORPHANOL MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 19. GLOBAL BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2023 VS 2030 (%)
FIGURE 21. GLOBAL BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES BUTORPHANOL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES BUTORPHANOL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. BUTORPHANOL MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. BUTORPHANOL MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BUTORPHANOL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BUTORPHANOL MARKET DYNAMICS
TABLE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY DAY PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BUTORPHANOL MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BUTORPHANOL MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BUTORPHANOL MARKET SIZE, BY PAIN MANAGEMENT SPECIALISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BUTORPHANOL MARKET SIZE, BY ICU MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BUTORPHANOL MARKET SIZE, BY PAIN MANAGEMENT TEAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME CARE PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BUTORPHANOL MARKET SIZE, BY PRESCRIPTION HOLDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BUTORPHANOL MARKET SIZE, BY ANALGESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BUTORPHANOL MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BUTORPHANOL MARKET SIZE, BY ANESTHESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BUTORPHANOL MARKET SIZE, BY CONSCIOUS SEDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BUTORPHANOL MARKET SIZE, BY PRE-ANESTHESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BUTORPHANOL MARKET SIZE, BY EPIDURAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BUTORPHANOL MARKET SIZE, BY SPINAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BUTORPHANOL MARKET SIZE, BY ACUTE MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BUTORPHANOL MARKET SIZE, BY PREVENTION OF MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BUTORPHANOL MARKET SIZE, BY MULTIPLE-USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BUTORPHANOL MARKET SIZE, BY SINGLE-USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BUTORPHANOL MARKET SIZE, BY OVER-THE-COUNTER SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BUTORPHANOL MARKET SIZE, BY PRESCRIPTION NASAL SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BUTORPHANOL MARKET SIZE, BY PATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BUTORPHANOL MARKET SIZE, BY LONG-TERM USAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BUTORPHANOL MARKET SIZE, BY SHORT-TERM USAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BUTORPHANOL MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BUTORPHANOL MARKET SIZE, BY QUICK-RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BUTORPHANOL MARKET SIZE, BY FULL ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BUTORPHANOL MARKET SIZE, BY PARTIAL AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BUTORPHANOL MARKET SIZE, BY PATIENT COMPLIANCE PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BUTORPHANOL MARKET SIZE, BY PRESCRIPTION REGULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BUTORPHANOL MARKET SIZE, BY POTENTIAL SCHEDULE ADJUSTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BUTORPHANOL MARKET SIZE, BY SCHEDULE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BUTORPHANOL MARKET SIZE, BY MULTIPLE DAILY DOSAGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BUTORPHANOL MARKET SIZE, BY SINGLE ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BUTORPHANOL MARKET SIZE, BY EFFECTIVE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BUTORPHANOL MARKET SIZE, BY TAPERING DOSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL BUTORPHANOL MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL BUTORPHANOL MARKET SIZE, BY AGE GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL BUTORPHANOL MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL BUTORPHANOL MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL BUTORPHANOL MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL BUTORPHANOL MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL BUTORPHANOL MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL BUTORPHANOL MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL BUTORPHANOL MARKET SIZE, BY ALLERGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL BUTORPHANOL MARKET SIZE, BY COMORBIDITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL BUTORPHANOL MARKET SIZE, BY PAIN CONDITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL BUTORPHANOL MARKET SIZE, BY BRAND DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL BUTORPHANOL MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 105. GLOBAL BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 106. GLOBAL BUTORPHANOL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 107. GLOBAL BUTORPHANOL MARKET SIZE, BY PRE-CLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 108. GLOBAL BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 109. GLOBAL BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 110. GLOBAL BUTORPHANOL MARKET SIZE, BY MEDICAL TRAINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 111. GLOBAL BUTORPHANOL MARKET SIZE, BY PATIENT AWARENESS PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 112. GLOBAL BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 132. AMERICAS BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. AMERICAS BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 134. AMERICAS BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. AMERICAS BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. AMERICAS BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 137. AMERICAS BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 138. AMERICAS BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 139. AMERICAS BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 140. AMERICAS BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 141. AMERICAS BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 142. AMERICAS BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 143. AMERICAS BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 144. AMERICAS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 207. CANADA BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 208. CANADA BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 209. CANADA BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 210. CANADA BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. CANADA BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 212. CANADA BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 213. CANADA BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 214. CANADA BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 215. CANADA BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 216. CANADA BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 217. CANADA BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. CANADA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 219. CANADA BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 220. CANADA BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 221. CANADA BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 222. CANADA BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 223. CANADA BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 224. CANADA BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 225. CANADA BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 226. CANADA BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 227. CANADA BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 228. CANADA BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. CANADA BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. CANADA BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. CANADA BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 232. CANADA BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 233. CANADA BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 234. CANADA BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 235. CANADA BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 236. CANADA BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 237. CANADA BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 238. MEXICO BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 239. MEXICO BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 240. MEXICO BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 241. MEXICO BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. MEXICO BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 243. MEXICO BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 244. MEXICO BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 245. MEXICO BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 246. MEXICO BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 247. MEXICO BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 248. MEXICO BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. MEXICO BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 250. MEXICO BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 251. MEXICO BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 252. MEXICO BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 253. MEXICO BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 254. MEXICO BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 255. MEXICO BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 256. MEXICO BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 257. MEXICO BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 258. MEXICO BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 259. MEXICO BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. MEXICO BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. MEXICO BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 262. MEXICO BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 263. MEXICO BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 264. MEXICO BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 265. MEXICO BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 266. MEXICO BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 267. MEXICO BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 268. MEXICO BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED STATES BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 270. UNITED STATES BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 271. UNITED STATES BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 272. UNITED STATES BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 273. UNITED STATES BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 274. UNITED STATES BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 275. UNITED STATES BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 276. UNITED STATES BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 277. UNITED STATES BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 278. UNITED STATES BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 279. UNITED STATES BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. UNITED STATES BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 281. UNITED STATES BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 282. UNITED STATES BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 283. UNITED STATES BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 284. UNITED STATES BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 285. UNITED STATES BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 286. UNITED STATES BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 287. UNITED STATES BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 288. UNITED STATES BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 289. UNITED STATES BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 290. UNITED STATES BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. UNITED STATES BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. UNITED STATES BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 293. UNITED STATES BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 294. UNITED STATES BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 295. UNITED STATES BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 296. UNITED STATES BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 297. UNITED STATES BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 298. UNITED STATES BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 299. UNITED STATES BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 300. UNITED STATES BUTORPHANOL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 310. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 311. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 313. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 314. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 315. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 316. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 317. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 318. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 319. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 320. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 321. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 322. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 325. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 326. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 327. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY HEALTH CONDITION, 2018-2030 (USD MILLION)
TABLE 328. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY INDUSTRY USAGE, 2018-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY TRAINING AND SIMULATION, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA BUTORPHANOL MARKET SIZE, BY END USER TYPE, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA BUTORPHANOL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA BUTORPHANOL MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA BUTORPHANOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA BUTORPHANOL MARKET SIZE, BY INDIVIDUAL CONSUMERS, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA BUTORPHANOL MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA BUTORPHANOL MARKET SIZE, BY ANALGESIA, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA BUTORPHANOL MARKET SIZE, BY ANESTHESIA, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA BUTORPHANOL MARKET SIZE, BY LABOR AND DELIVERY, 2018-2030 (USD MILLION)
TABLE 342. AUSTRALIA BUTORPHANOL MARKET SIZE, BY MIGRAINE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 343. AUSTRALIA BUTORPHANOL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 344. AUSTRALIA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 345. AUSTRALIA BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, 2018-2030 (USD MILLION)
TABLE 346. AUSTRALIA BUTORPHANOL MARKET SIZE, BY PATCH, 2018-2030 (USD MILLION)
TABLE 347. AUSTRALIA BUTORPHANOL MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 348. AUSTRALIA BUTORPHANOL MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 349. AUSTRALIA BUTORPHANOL MARKET SIZE, BY AGONIST-ANTAGONIST OPIOID, 2018-2030 (USD MILLION)
TABLE 350. AUSTRALIA BUTORPHANOL MARKET SIZE, BY CONTROLLED SUBSTANCES, 2018-2030 (USD MILLION)
TABLE 351. AUSTRALIA BUTORPHANOL MARKET SIZE, BY SCHEDULED DRUGS, 2018-2030 (USD MILLION)
TABLE 352. AUSTRALIA BUTORPHANOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 353. AUSTRALIA BUTORPHANOL MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2030 (USD MILLION)
TABLE 354. AUSTRALIA BUTORPHANOL MARKET SIZE, BY MILLIGRAMS PER ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 355. AUSTRALIA BUTORPHANOL MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 356. AUSTRALIA BUTORPHANOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 357. AUSTRALIA BUTORPHANOL MARKET SIZE, BY AGE GROUPS, 2018-2030 (USD MILLION)
TABLE 358. AUSTRALIA BUTORPHANOL MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 359. AUSTRALIA BUTORPHANOL MARKET SIZE, BY HE

Companies Mentioned

  • Akorn, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma USA, Inc.
  • BioDelivery Sciences International, Inc.
  • Egalet Corporation
  • Endo Pharmaceuticals Inc.
  • Esteve Pharmaceuticals
  • Fresenius Kabi USA, LLC
  • Hikma Pharmaceuticals PLC
  • Hospira, Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt Pharmaceuticals
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedNovember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 283.74 million
Forecasted Market Value ( USD ) by 2030 $ 364.75 million
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Butorphanol Tartrate Injection Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Butorphanol Tartrate Injection Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 80 Pages
  • Global
From
Butorphanol (CAS 42408-82-2) Global Market Research Report 2024 - Product Image

Butorphanol (CAS 42408-82-2) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Plumb's Veterinary Drug Handbook. Edition No. 10 - Product Image

Plumb's Veterinary Drug Handbook. Edition No. 10

  • Book
  • 1568 Pages
Migraine Drugs Market by Therapeutic Class, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030 - Product Image

Migraine Drugs Market by Therapeutic Class, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Cancer Pain Management Market by Drug Type, Route of Administration, Application, End-Use - Global Forecast 2025-2030 - Product Image

Cancer Pain Management Market by Drug Type, Route of Administration, Application, End-Use - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From

About the Butorphanol Market

Butorphanol is an analgesic drug used to treat moderate to severe pain. It is a synthetic opioid agonist-antagonist, meaning it has both agonist and antagonist properties. It is a Schedule IV controlled substance in the United States, meaning it has a low potential for abuse and dependence. Butorphanol is available in both intranasal and injectable forms, and is commonly used in the treatment of migraine headaches, postoperative pain, and labor pain. It is also used to treat opioid withdrawal symptoms. Butorphanol is generally considered to be a safe and effective analgesic, with few side effects. Common side effects include nausea, dizziness, and drowsiness. It is important to note that butorphanol should not be used in combination with other opioids, as this can increase the risk of serious side effects. Some companies in the butorphanol market include Endo Pharmaceuticals, Mylan Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.